O	0	4	Long
O	4	5	-
O	5	9	term
O	10	17	Effects
O	18	20	of
O	21	33	Intravitreal
O	34	35	0
O	35	36	.
O	36	38	19
O	39	41	mg
O	42	54	Fluocinolone
O	55	64	Acetonide
O	65	72	Implant
O	73	75	on
O	76	87	Progression
O	88	91	and
O	92	102	Regression
O	103	105	of
B-Disease	106	114	Diabetic
I-Disease	115	126	Retinopathy
O	126	127	.

O	129	131	To
O	132	143	investigate
O	144	147	the
O	148	155	effects
O	156	158	of
O	159	171	fluocinolone
O	172	181	acetonide
O	182	183	(
O	183	186	FAc
O	186	187	)
O	188	190	on
O	191	194	the
O	195	206	progression
O	207	209	to
B-Disease	210	223	proliferative
I-Disease	224	232	diabetic
I-Disease	233	244	retinopathy
O	245	246	(
B-Disease	246	249	PDR
O	249	250	)
O	251	254	and
O	255	258	the
O	259	265	impact
O	266	268	of
O	269	272	FAc
O	273	275	on
O	276	283	changes
O	284	286	in
O	287	292	Early
O	293	302	Treatment
B-Disease	303	311	Diabetic
I-Disease	312	323	Retinopathy
O	324	329	Study
O	330	331	(
O	331	336	ETDRS
O	336	337	)
B-Classification_system	338	346	diabetic
I-Classification_system	347	358	retinopathy
I-Classification_system	359	360	(
I-Classification_system	360	362	DR
I-Classification_system	362	363	)
I-Classification_system	364	372	severity
I-Classification_system	373	378	scale
O	379	380	(
B-Classification_system	380	384	DRSS
O	384	385	)
O	386	391	grade
O	392	398	during
O	399	402	the
O	403	415	Fluocinolone
O	416	425	Acetonide
O	426	428	in
B-Disease	429	437	Diabetic
I-Disease	438	445	Macular
I-Disease	446	451	Edema
O	452	453	(
O	453	457	FAME
O	457	458	)
O	459	460	A
O	461	464	and
O	465	466	B
O	467	472	Phase
O	473	476	III
O	477	485	clinical
O	486	492	trials
O	492	493	.

O	494	498	Post
O	499	502	hoc
O	503	511	analysis
O	512	514	of
O	515	519	data
O	520	524	from
O	525	528	the
O	529	531	36
O	531	532	-
O	532	537	month
O	538	549	prospective
O	549	550	,
O	551	561	randomized
O	561	562	,
O	563	567	FAME
O	568	569	A
O	570	573	and
O	574	575	B
O	576	582	trials
O	582	583	.

O	584	592	Patients
O	593	597	with
B-Disease	598	606	diabetic
I-Disease	607	614	macular
I-Disease	615	620	edema
O	621	622	(
B-Disease	622	625	DME
O	625	626	)
O	627	630	who
O	631	639	received
O	640	644	sham
O	645	652	control
O	653	655	or
O	656	659	FAc
O	660	661	0
O	661	662	.
O	662	663	2
O	664	666	or
O	667	668	0
O	668	669	.
O	669	670	5
O	671	672	μ
O	672	673	g
O	673	674	/
O	674	677	day
O	677	678	.

O	679	680	A
O	681	687	masked
O	688	695	reading
O	696	702	center
O	703	704	(
O	704	714	University
O	715	717	of
O	718	727	Wisconsin
O	727	728	-
O	728	735	Madison
O	735	736	)
O	737	747	determined
B-Classification_system	748	752	DRSS
O	753	758	grade
O	759	762	and
B-Characteristic	763	770	retinal
I-Characteristic	771	780	perfusion
O	781	787	status
O	788	793	using
O	794	802	standard
B-Diagnostic_tool	803	804	7
I-Diagnostic_tool	804	805	-
I-Diagnostic_tool	805	810	field
I-Diagnostic_tool	811	817	stereo
I-Diagnostic_tool	818	824	fundus
I-Diagnostic_tool	825	836	photography
O	837	840	and
B-Diagnostic_tool	841	852	fluorescein
I-Diagnostic_tool	853	864	angiography
O	864	865	,
O	866	878	respectively
O	878	879	.

B-Disease	880	891	Retinopathy
O	892	899	changes
O	900	904	over
O	905	909	time
O	910	914	were
O	915	925	determined
O	926	928	by
B-Classification_system	929	933	DRSS
O	934	938	step
O	939	950	differences
O	951	955	from
O	956	964	baseline
O	965	967	to
O	968	973	month
O	974	976	36
O	976	977	.

O	978	986	Pairwise
O	987	998	comparisons
O	999	1006	between
O	1007	1010	the
O	1011	1012	3
O	1013	1022	treatment
O	1023	1029	groups
O	1030	1034	were
O	1035	1044	performed
O	1045	1050	using
O	1051	1052	a
O	1053	1056	log
O	1056	1057	-
O	1057	1061	rank
O	1062	1066	test
O	1067	1074	without
O	1075	1085	adjustment
O	1086	1089	for
O	1090	1100	covariates
O	1100	1101	,
O	1102	1106	with
O	1107	1110	the
O	1111	1118	primary
O	1119	1129	comparison
O	1130	1137	between
O	1138	1142	sham
O	1143	1150	control
O	1151	1154	and
O	1155	1156	0
O	1156	1157	.
O	1157	1158	2
O	1159	1160	μ
O	1160	1161	g
O	1161	1162	/
O	1162	1165	day
O	1166	1169	FAc
O	1169	1170	.

O	1171	1176	Study
B-Anatomy	1177	1180	eye
O	1181	1192	progression
O	1193	1195	to
B-Disease	1196	1199	PDR
O	1200	1205	based
O	1206	1208	on
O	1209	1210	a
O	1211	1220	composite
O	1221	1229	clinical
O	1230	1237	outcome
O	1238	1240	of
O	1241	1242	(
O	1242	1243	1
O	1243	1244	)
O	1245	1256	progression
O	1257	1261	from
B-Disease	1262	1278	nonproliferative
I-Disease	1279	1287	diabetic
I-Disease	1288	1299	retinopathy
O	1300	1301	(
B-Disease	1301	1305	NPDR
O	1305	1306	)
O	1307	1309	to
B-Disease	1310	1313	PDR
O	1314	1319	based
O	1320	1322	on
O	1323	1329	graded
B-Diagnostic_tool	1330	1336	fundus
I-Diagnostic_tool	1337	1348	photographs
O	1348	1349	,
O	1350	1351	(
O	1351	1352	2
O	1352	1353	)
B-Diagnostic_tool	1354	1364	panretinal
I-Diagnostic_tool	1365	1381	photocoagulation
O	1382	1383	(
B-Diagnostic_tool	1383	1386	PRP
O	1386	1387	)
O	1387	1388	,
O	1389	1391	or
O	1392	1393	(
O	1393	1394	3
O	1394	1395	)
B-Diagnostic_tool	1396	1400	pars
I-Diagnostic_tool	1401	1406	plana
I-Diagnostic_tool	1407	1417	vitrectomy
O	1418	1419	(
B-Diagnostic_tool	1419	1422	PPV
O	1422	1423	)
O	1424	1427	for
B-Disease	1428	1431	PDR
O	1431	1432	;
O	1433	1436	and
O	1437	1442	study
B-Anatomy	1443	1446	eye
O	1447	1454	changes
O	1455	1457	on
O	1458	1461	the
B-Classification_system	1462	1466	DRSS
O	1466	1467	.

O	1468	1470	In
O	1471	1474	the
O	1475	1485	integrated
O	1486	1490	FAME
O	1491	1495	data
O	1496	1499	set
O	1499	1500	,
O	1501	1509	compared
O	1510	1514	with
O	1515	1519	sham
O	1520	1527	control
O	1527	1528	-
O	1528	1535	treated
O	1536	1544	subjects
O	1544	1545	,
O	1546	1550	time
O	1551	1553	to
O	1554	1559	first
B-Disease	1560	1563	PDR
O	1564	1569	event
O	1570	1573	was
O	1574	1587	significantly
O	1588	1595	delayed
O	1596	1598	in
O	1599	1607	subjects
O	1608	1615	treated
O	1616	1620	with
O	1621	1624	FAc
O	1625	1626	(
O	1626	1627	P
O	1629	1630	<
O	1632	1633	0
O	1633	1634	.
O	1634	1637	001
O	1637	1638	)
O	1638	1639	,
O	1640	1643	and
O	1644	1648	this
O	1649	1655	effect
O	1656	1659	was
O	1660	1669	confirmed
O	1670	1672	in
O	1673	1682	subgroups
O	1683	1687	with
O	1688	1692	more
O	1693	1699	severe
B-Disease	1700	1702	DR
O	1703	1706	and
B-Disease	1707	1714	chronic
I-Disease	1715	1718	DME
O	1719	1721	at
O	1722	1730	baseline
O	1730	1731	.

O	1732	1734	In
O	1735	1743	addition
O	1743	1744	,
O	1745	1753	subjects
O	1754	1758	with
B-Symptom	1759	1766	retinal
I-Symptom	1767	1779	nonperfusion
O	1780	1782	at
O	1783	1791	baseline
O	1792	1798	showed
O	1799	1806	greater
O	1807	1816	reduction
O	1817	1819	in
O	1820	1831	progression
O	1832	1834	to
B-Disease	1835	1838	PDR
O	1839	1843	with
O	1844	1847	FAc
O	1848	1857	treatment
O	1857	1858	.

O	1859	1863	Both
O	1864	1867	FAc
O	1868	1875	dosages
O	1876	1888	demonstrated
O	1889	1902	statistically
O	1903	1914	significant
O	1915	1927	improvements
O	1928	1930	in
O	1931	1935	mean
B-Disease	1936	1938	DR
O	1939	1947	severity
O	1948	1956	compared
O	1957	1961	with
O	1962	1966	sham
O	1967	1976	treatment
O	1977	1979	at
O	1980	1986	months
O	1987	1988	6
O	1988	1989	,
O	1990	1992	12
O	1992	1993	,
O	1994	1997	and
O	1998	2000	18
O	2000	2001	.

O	2002	2013	Numerically
O	2014	2018	more
O	2019	2027	subjects
O	2028	2031	who
O	2032	2040	received
O	2041	2044	FAc
O	2045	2056	experienced
O	2057	2058	2
O	2058	2059	-
O	2059	2061	or
O	2061	2062	-
O	2062	2066	more
O	2066	2067	-
O	2068	2070	or
O	2071	2072	3
O	2072	2073	-
O	2073	2075	or
O	2075	2076	-
O	2076	2080	more
O	2080	2081	-
O	2081	2085	step
O	2086	2098	improvements
O	2099	2101	in
B-Disease	2102	2104	DR
O	2105	2113	severity
O	2114	2122	compared
O	2123	2127	with
O	2128	2136	subjects
O	2137	2140	who
O	2141	2149	received
O	2150	2154	sham
O	2154	2155	;
O	2156	2166	conversely
O	2166	2167	,
O	2168	2173	fewer
O	2174	2182	subjects
O	2183	2190	treated
O	2191	2195	with
O	2196	2199	FAc
O	2200	2211	experienced
O	2212	2213	2
O	2213	2214	-
O	2214	2216	or
O	2216	2217	-
O	2217	2221	more
O	2221	2222	-
O	2223	2225	or
O	2226	2227	3
O	2227	2228	-
O	2228	2230	or
O	2230	2231	-
O	2231	2235	more
O	2235	2236	-
O	2236	2240	step
O	2241	2250	worsening
O	2251	2253	in
B-Disease	2254	2256	DR
O	2257	2265	severity
O	2265	2266	.

O	2267	2270	The
O	2271	2272	3
O	2272	2273	-
O	2273	2275	or
O	2275	2276	-
O	2276	2280	more
O	2280	2281	-
O	2281	2285	step
O	2286	2297	improvement
O	2298	2302	with
O	2303	2304	0
O	2304	2305	.
O	2305	2306	5
O	2307	2308	μ
O	2308	2309	g
O	2309	2310	/
O	2310	2313	day
O	2314	2317	FAc
O	2318	2321	was
O	2322	2335	statistically
O	2336	2349	significantly
O	2350	2359	different
O	2360	2364	from
O	2365	2369	sham
O	2370	2377	control
O	2377	2378	.

O	2379	2381	In
O	2382	2390	subjects
O	2391	2395	with
B-Disease	2396	2399	DME
O	2399	2400	,
O	2401	2410	sustained
O	2411	2422	intraocular
O	2423	2431	delivery
O	2432	2434	of
O	2435	2438	FAc
O	2439	2444	slows
O	2445	2456	development
O	2457	2459	of
B-Disease	2460	2463	PDR
O	2464	2467	and
O	2468	2473	slows
O	2474	2485	progression
O	2486	2488	of
B-Disease	2489	2497	diabetic
I-Disease	2498	2509	retinopathy
O	2509	2510	.
